Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Plentz, Ruben
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer	Completed	2	124	Europe	Aflibercept + mLV5FU2, mFOLFOX7	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi	Colorectal Cancer	02/24	02/24
Bitzer, Michael
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	Recruiting	2	106	Europe	Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE)	Ludwig-Maximilians - University of Munich	Hepatocellular Carcinoma Non-resectable	03/25	03/25
CRAFT, NCT04551521 / 2019-003192-18: The NCT-PMO-1602 Phase II Trial	Completed	2	72	Europe	Vemurafenib, Cobimetinib, Atezolizumab, Trastuzumab, Pertuzumab, Alectinib, Ipatasertib, Inavolisib	German Cancer Research Center, German Cancer Research Center, Roche Pharma AG	Metastatic or Locally Advanced Malignancies	12/24	12/24
NCT05174650 / 2020-004938-38: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements	Active, not recruiting	2	27	Europe	Atezolizumab, Tecentriq, Derazantinib, ARQ 087	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd.	Intrahepatic Cholangiocarcinoma	12/25	08/26
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer	Completed	1/2	29	Europe, US	MEN1611, Cetuximab	Menarini Group, Menarini Ricerche S.p.A.	Metastatic Colorectal Cancer	01/24	02/24
HCC-e:Med2, NCT03958669: Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC	Terminated	N/A	2	Europe		University Hospital Tuebingen, German Federal Ministry of Education and Research	Hepatocellular Carcinoma, Sorafenib	12/22	05/23